MarketWatchCenter·
Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
Read at MarketWatch →
The U.S. regulator’s disclosure was more extensive than what the biotech company had announced Sunday.
<iframe src="https://statesidedaily.com/embed/cluster/d804d2077fc4c335af8d2f1b12c33e61241f9b5a" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Summit Therapeutics’ stock tumbles again as FDA recommends new trial for lung-cancer drug"></iframe>